Updates are available Correction dated 2021-01-19
Click to view Correction: https://doi.org/10.1038/s41586-020-03099-2
-
Authors
van Doremalen, Neeltje https://orcid.org/0000-0003-4368-6359
Lambe, Teresa https://orcid.org/0000-0001-7711-897X
Spencer, Alexandra https://orcid.org/0000-0001-7958-6961
Belij-Rammerstorfer, Sandra
Purushotham, Jyothi N.
Port, Julia R.
Avanzato, Victoria A.
Bushmaker, Trenton
Flaxman, Amy
Ulaszewska, Marta
Feldmann, Friederike
Allen, Elizabeth R. https://orcid.org/0000-0002-6406-4834
Sharpe, Hannah https://orcid.org/0000-0002-1194-2429
Schulz, Jonathan
Holbrook, Myndi
Okumura, Atsushi
Meade-White, Kimberly
Pérez-Pérez, Lizzette
Edwards, Nick J. https://orcid.org/0000-0002-7030-7839
Wright, Daniel https://orcid.org/0000-0002-8114-1838
Bissett, Cameron
Gilbride, Ciaran
Williamson, Brandi N.
Rosenke, Rebecca
Long, Dan
Ishwarbhai, Alka
Kailath, Reshma
Rose, Louisa
Morris, Susan
Powers, Claire
Lovaglio, Jamie
Hanley, Patrick W.
Scott, Dana
Saturday, Greg
de Wit, Emmie https://orcid.org/0000-0002-9763-7758
Gilbert, Sarah C. https://orcid.org/0000-0002-6823-9750
Munster, Vincent J. https://orcid.org/0000-0002-2288-3196
- License Information
-
More Information
Article History
Received: 13 May 2020
Accepted: 24 July 2020
First Online: 30 July 2020
Change Date: 19 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published: https://doi.org/10.1038/s41586-020-03099-2
Competing interests
: S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering the use of ChAdOx1-vector-based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and Vaccitech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor Vaccitech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. The other authors declare no competing interests.
Free to read: This content has been made available to all.
